Abstract
Idiopathic pulmonary fibrosis is the most common and lethal form of interstitial lung diseases, with an associated median survival of only 2 to 3 years. Doxycycline through its matrix metalloproteinase inhibition property may be useful in slowing the disease progression among patients with ILD. However, there are only anecdotal reports in the literature in demonstrating long term trajectory in lung function parameters and radiology progress among IPF patients treated with doxycycline. In this report we describe the clinical course of two patients with IPF treated with doxycycline. We also compared the decline in the pulmonary function parameters in our patients with previously published predicted values for normal ageing (non-IPF), placebo, nintedanib and pirfenidone treated patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.